Two recent clinical studies reported the efficacy of anti-PD1 therapy with nivolumab in patients with ALK+ ALCL refractory to chemotherapy and ALK inhibitors [107,108]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.